Carfilzomib

被引：162
作者：
Kortuem, K. Martin [1 ]
Stewart, A. Keith [1 ]
机构：
[1] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA
来源：
BLOOD | 2013年 / 121卷 / 06期
关键词：
UNFOLDED PROTEIN RESPONSE; SINGLE-AGENT CARFILZOMIB; PROTEASOME INHIBITOR CARFILZOMIB; REFRACTORY MULTIPLE-MYELOMA; 20 S PROTEASOME; ENDOPLASMIC-RETICULUM; OPEN-LABEL; BORTEZOMIB RESISTANCE; SELECTIVE INHIBITORS; THERAPEUTIC TARGET;
D O I：
10.1182/blood-2012-10-459883
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This spotlight review focuses on the second-generation proteasome inhibitor carfilzomib, which was recently approved by the US Food and Drug Administration for treatment of relapsed and refractory multiple myeloma patients who have received at least 2 prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy. This review focuses on clinical trial data leading to drug approval and provides advice for treating physicians who are now accessing this drug for patients. (Blood. 2013;121(6):893-897)
引用
收藏
页码：893 / 897
页数：5
相关论文
共 79 条
  • [31] NF-κB as a therapeutic target in multiple myeloma
    Hideshima, T
    Chauhan, D
    Richardson, P
    Mitsiades, C
    Mitsiades, N
    Hayashi, T
    Munshi, N
    Dang, L
    Castro, A
    Palombella, V
    Adams, J
    Anderson, KC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (19) : 16639 - 16647
  • [32] LMP2-specific inhibitors: Chemical genetic tools for proteasome biology
    Ho, Yik Khuan
    Bargagna-Mohan, Paola
    Wehenkel, Marie
    Mohan, Royce
    Kim, Kyung-Bo
    [J]. CHEMISTRY & BIOLOGY, 2007, 14 (04): : 419 - 430
  • [33] Regulation of monoubiquitinated PCNA by DUB autocleavage
    Huang, TT
    Nijman, SMB
    Mirchandani, KD
    Galardy, PJ
    Cohn, MA
    Haas, W
    Gygi, SP
    Ploegh, HL
    Bernards, R
    D'Andrea, AD
    [J]. NATURE CELL BIOLOGY, 2006, 8 (04) : 339 - U13
  • [34] Regulation of DNA repair by ubiquitylation
    Huang, TT
    D'Andrea, AD
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2006, 7 (05) : 323 - 334
  • [35] A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
    Jakubowiak, Andrzej J.
    Dytfeld, Dominik
    Griffith, Kent A.
    Lebovic, Daniel
    Vesole, David H.
    Jagannath, Sundar
    Al-Zoubi, Ammar
    Anderson, Tara
    Nordgren, Brian
    Detweiler-Short, Kristen
    Stockerl-Goldstein, Keith
    Ahmed, Asra
    Jobkar, Terri
    Durecki, Diane E.
    McDonnell, Kathryn
    Mietzel, Melissa
    Couriel, Daniel
    Kaminski, Mark
    Vij, Ravi
    [J]. BLOOD, 2012, 120 (09) : 1801 - 1809
  • [36] Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls
    Kaufman, RJ
    [J]. GENES & DEVELOPMENT, 1999, 13 (10) : 1211 - 1233
  • [37] How proteolysis drives the cell cycle
    King, RW
    Deshaies, RJ
    Peters, JM
    Kirschner, MW
    [J]. SCIENCE, 1996, 274 (5293) : 1652 - 1659
  • [38] Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate
    Kisselev, AF
    Callard, A
    Goldberg, AL
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (13) : 8582 - 8590
  • [39] Antigen processing by the proteasome
    Kloetzel, PM
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (03) : 179 - 187
  • [40] Kolb B, 2012, ASCO M ABSTRACTS S, V30, P8009
12345678